3,527 Shares in Icon Plc $ICLR Purchased by Storgate LLC

Storgate LLC acquired a new position in shares of Icon Plc (NASDAQ:ICLR) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,527 shares of the medical research company’s stock, valued at approximately $643,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ICLR. Harris Associates L P acquired a new stake in Icon during the second quarter worth about $238,256,000. Capital World Investors increased its position in Icon by 555.2% during the fourth quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock worth $272,688,000 after purchasing an additional 1,268,095 shares during the last quarter. Wellington Management Group LLP increased its position in Icon by 26.6% during the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after purchasing an additional 975,268 shares during the last quarter. Lyrical Asset Management LP acquired a new stake in Icon during the fourth quarter worth about $176,382,000. Finally, Norges Bank acquired a new stake in Icon during the fourth quarter worth about $160,073,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Trading Down 2.5%

NASDAQ ICLR opened at $146.18 on Friday. The firm has a 50 day simple moving average of $121.76 and a 200-day simple moving average of $140.47. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.10. Icon Plc has a one year low of $66.57 and a one year high of $211.00. The firm has a market cap of $11.19 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 11.84 and a beta of 1.26.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, June 17th. The medical research company reported $2.52 EPS for the quarter, beating the consensus estimate of $2.47 by $0.05. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion during the quarter, compared to analyst estimates of $1.99 billion. During the same quarter last year, the firm posted $3.43 earnings per share. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. Equities research analysts anticipate that Icon Plc will post 9.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ICLR shares. Weiss Ratings cut shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Bank of America reiterated an “outperform” rating on shares of Icon in a research report on Monday, June 1st. Rothschild & Co Redburn set a $100.00 price target on shares of Icon and gave the company a “neutral” rating in a research report on Tuesday, February 17th. JPMorgan Chase & Co. lifted their price target on shares of Icon from $120.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, May 29th. Finally, BMO Capital Markets lifted their price target on shares of Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a research report on Friday, May 29th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Icon currently has a consensus rating of “Hold” and an average price target of $156.44.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.